Low Omicron BA.4 and BA.5 neutralising activity and breakthrough COVID-19 following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated patients with autoimmune disease

Affiliations

• ¹ Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ² Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ³ Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ⁴ Department of Surgery, NYU Grossman School of Medicine, New York, NY, USA.
• ⁵ Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jpaik1@jhmi.edu.